Saudi Arabia Guidelines for diabetic macular edema A consensus of the Saudi Retina Group
Diabetes mellitus (DM) and its complications are major public health burdens in Saudi Arabia. The prevalence of diabetic retinopathy (DR) is 19.7% and the prevalence of diabetic macular edema (DME) is 5.7% in Saudi Arabia. Diabetic macular edema is a vision-threatening complication of DR and a major...
Gespeichert in:
| Veröffentlicht in: | Saudi medical journal 2021-02, Vol.42 (2), p.131-145 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 145 |
|---|---|
| container_issue | 2 |
| container_start_page | 131 |
| container_title | Saudi medical journal |
| container_volume | 42 |
| creator | AlQahtani, Abdullah S. Hazzazi, Mohammad A. Waheeb, Saad A. Semidey, Valmore A. Elgendy, Hussein K. Alkhars, Wafeeha Abouammoh, Marwan A. Al-Dhibi, Hassan |
| description | Diabetes mellitus (DM) and its complications are major public health burdens in Saudi Arabia. The prevalence of diabetic retinopathy (DR) is 19.7% and the prevalence of diabetic macular edema (DME) is 5.7% in Saudi Arabia. Diabetic macular edema is a vision-threatening complication of DR and a major cause of vision loss worldwide. Ocular treatments include retinal laser photocoagulation, anti-vascular endothelial growth factor (anti-VEGF) agents, intravitreal corticosteroids, and vitreoretinal surgery when necessary. The present consensus was developed as a part of the Saudi Retina Group's efforts to generate Saudi guidelines and consensus for the management of DME, including recommendations for its diagnosis, treatment, and best practice. The experts' panel stipulates that the treatment algorithm should be categorized according to the presence of central macula involvement. In patients with no central macular involvement, laser photocoagulation is recommended as the first-line option. Patients with central macular involvement and no recent history of cardiovascular (CVS) or cerebrovascular disorders can be offered anti-VEGF agents as the first-line option. In the case of non-responders (defined as an improvement of |
| doi_str_mv | 10.15537/smj.2021.2.25623 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000619808700001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A652179152</galeid><sourcerecordid>A652179152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-c147c891692deca2dc18655633d409ec904aae33fc20aad5504634f8581fafa23</originalsourceid><addsrcrecordid>eNqNkUuLFDEUhYMoTjv6A9xIwKVUmUcllWyEptEZYUDwAe7C7TxmMlQlTaVK8d-bnnIaB1xIFgnJd869uQehl5S0VAjevy3jbcsIoy1rmZCMP0IbKoVqOO3FY7QhvNeNYKo7Q89KuSWES0nkU3TGuZC853SDvn-BxUW8nWAfAV8s0fkhJl9wyBN2EfZ-jhaPYJcBJuydHwFvsc2p-FSWgnPA843Hq8vnCqfqMuXl8Bw9CTAU_-LPfo6-fXj_dXfZXH26-LjbXjWW92JuLO16qzSVmjlvgTlLlRS1O-46or3VpAPwnAfLCIATgnSSd0EJRQMEYPwcvVt9D8t-9M76NE8wmMMUR5h-mQzRPHxJ8cZc5x-m10ozzavB69XgGgZvYgq5YnaMxZqtFIz2mopjmfYfVF11IrGOw4dY7x8I6CqwUy5l8uHUEiXmLj1T0zPH9Awzd-lVzau__3JS3MdVgTcr8NPvcyg2-mT9CSOESKoVUX09kSOt_p_exRnmmNMuL2nmvwENVLZ6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Saudi Arabia Guidelines for diabetic macular edema A consensus of the Saudi Retina Group</title><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>AlQahtani, Abdullah S. ; Hazzazi, Mohammad A. ; Waheeb, Saad A. ; Semidey, Valmore A. ; Elgendy, Hussein K. ; Alkhars, Wafeeha ; Abouammoh, Marwan A. ; Al-Dhibi, Hassan</creator><creatorcontrib>AlQahtani, Abdullah S. ; Hazzazi, Mohammad A. ; Waheeb, Saad A. ; Semidey, Valmore A. ; Elgendy, Hussein K. ; Alkhars, Wafeeha ; Abouammoh, Marwan A. ; Al-Dhibi, Hassan</creatorcontrib><description>Diabetes mellitus (DM) and its complications are major public health burdens in Saudi Arabia. The prevalence of diabetic retinopathy (DR) is 19.7% and the prevalence of diabetic macular edema (DME) is 5.7% in Saudi Arabia. Diabetic macular edema is a vision-threatening complication of DR and a major cause of vision loss worldwide. Ocular treatments include retinal laser photocoagulation, anti-vascular endothelial growth factor (anti-VEGF) agents, intravitreal corticosteroids, and vitreoretinal surgery when necessary. The present consensus was developed as a part of the Saudi Retina Group's efforts to generate Saudi guidelines and consensus for the management of DME, including recommendations for its diagnosis, treatment, and best practice. The experts' panel stipulates that the treatment algorithm should be categorized according to the presence of central macula involvement. In patients with no central macular involvement, laser photocoagulation is recommended as the first-line option. Patients with central macular involvement and no recent history of cardiovascular (CVS) or cerebrovascular disorders can be offered anti-VEGF agents as the first-line option. In the case of non-responders (defined as an improvement of <20% in optical coherence tomography or a gain of fewer than 5 letters in vision), switching to another anti-VEGF agent or steroids should be considered after 3 injections. Within the class of steroids, dexamethasone implants are recommended as the first choice. In patients with a recent history of CVS events, the use of anti-VEGF agents is not recommended, regardless of their lens status. The experts' panel recommends that a future study be conducted to provide a cut-off point for early switching to steroid implants in pseudo-phakic eyes.</description><identifier>ISSN: 0379-5284</identifier><identifier>EISSN: 1658-3175</identifier><identifier>DOI: 10.15537/smj.2021.2.25623</identifier><identifier>PMID: 33563731</identifier><language>eng</language><publisher>RIYADH: Saudi Med J</publisher><subject>Care and treatment ; Causes of ; Clinical Practice Guidelines ; Diabetic retinopathy ; Diagnosis ; Eye diseases ; General & Internal Medicine ; Life Sciences & Biomedicine ; Medicine, General & Internal ; Practice guidelines (Medicine) ; Science & Technology</subject><ispartof>Saudi medical journal, 2021-02, Vol.42 (2), p.131-145</ispartof><rights>Copyright: © Saudi Medical Journal.</rights><rights>COPYRIGHT 2021 Saudi Medical Journal</rights><rights>Copyright: © Saudi Medical Journal 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000619808700001</woscitedreferencesoriginalsourcerecordid><cites>FETCH-LOGICAL-c375t-c147c891692deca2dc18655633d409ec904aae33fc20aad5504634f8581fafa23</cites><orcidid>0000-0002-0621-1234</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989293/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989293/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,39263,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33563731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>AlQahtani, Abdullah S.</creatorcontrib><creatorcontrib>Hazzazi, Mohammad A.</creatorcontrib><creatorcontrib>Waheeb, Saad A.</creatorcontrib><creatorcontrib>Semidey, Valmore A.</creatorcontrib><creatorcontrib>Elgendy, Hussein K.</creatorcontrib><creatorcontrib>Alkhars, Wafeeha</creatorcontrib><creatorcontrib>Abouammoh, Marwan A.</creatorcontrib><creatorcontrib>Al-Dhibi, Hassan</creatorcontrib><title>Saudi Arabia Guidelines for diabetic macular edema A consensus of the Saudi Retina Group</title><title>Saudi medical journal</title><addtitle>SAUDI MED J</addtitle><addtitle>Saudi Med J</addtitle><description>Diabetes mellitus (DM) and its complications are major public health burdens in Saudi Arabia. The prevalence of diabetic retinopathy (DR) is 19.7% and the prevalence of diabetic macular edema (DME) is 5.7% in Saudi Arabia. Diabetic macular edema is a vision-threatening complication of DR and a major cause of vision loss worldwide. Ocular treatments include retinal laser photocoagulation, anti-vascular endothelial growth factor (anti-VEGF) agents, intravitreal corticosteroids, and vitreoretinal surgery when necessary. The present consensus was developed as a part of the Saudi Retina Group's efforts to generate Saudi guidelines and consensus for the management of DME, including recommendations for its diagnosis, treatment, and best practice. The experts' panel stipulates that the treatment algorithm should be categorized according to the presence of central macula involvement. In patients with no central macular involvement, laser photocoagulation is recommended as the first-line option. Patients with central macular involvement and no recent history of cardiovascular (CVS) or cerebrovascular disorders can be offered anti-VEGF agents as the first-line option. In the case of non-responders (defined as an improvement of <20% in optical coherence tomography or a gain of fewer than 5 letters in vision), switching to another anti-VEGF agent or steroids should be considered after 3 injections. Within the class of steroids, dexamethasone implants are recommended as the first choice. In patients with a recent history of CVS events, the use of anti-VEGF agents is not recommended, regardless of their lens status. The experts' panel recommends that a future study be conducted to provide a cut-off point for early switching to steroid implants in pseudo-phakic eyes.</description><subject>Care and treatment</subject><subject>Causes of</subject><subject>Clinical Practice Guidelines</subject><subject>Diabetic retinopathy</subject><subject>Diagnosis</subject><subject>Eye diseases</subject><subject>General & Internal Medicine</subject><subject>Life Sciences & Biomedicine</subject><subject>Medicine, General & Internal</subject><subject>Practice guidelines (Medicine)</subject><subject>Science & Technology</subject><issn>0379-5284</issn><issn>1658-3175</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkUuLFDEUhYMoTjv6A9xIwKVUmUcllWyEptEZYUDwAe7C7TxmMlQlTaVK8d-bnnIaB1xIFgnJd869uQehl5S0VAjevy3jbcsIoy1rmZCMP0IbKoVqOO3FY7QhvNeNYKo7Q89KuSWES0nkU3TGuZC853SDvn-BxUW8nWAfAV8s0fkhJl9wyBN2EfZ-jhaPYJcBJuydHwFvsc2p-FSWgnPA843Hq8vnCqfqMuXl8Bw9CTAU_-LPfo6-fXj_dXfZXH26-LjbXjWW92JuLO16qzSVmjlvgTlLlRS1O-46or3VpAPwnAfLCIATgnSSd0EJRQMEYPwcvVt9D8t-9M76NE8wmMMUR5h-mQzRPHxJ8cZc5x-m10ozzavB69XgGgZvYgq5YnaMxZqtFIz2mopjmfYfVF11IrGOw4dY7x8I6CqwUy5l8uHUEiXmLj1T0zPH9Awzd-lVzau__3JS3MdVgTcr8NPvcyg2-mT9CSOESKoVUX09kSOt_p_exRnmmNMuL2nmvwENVLZ6</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>AlQahtani, Abdullah S.</creator><creator>Hazzazi, Mohammad A.</creator><creator>Waheeb, Saad A.</creator><creator>Semidey, Valmore A.</creator><creator>Elgendy, Hussein K.</creator><creator>Alkhars, Wafeeha</creator><creator>Abouammoh, Marwan A.</creator><creator>Al-Dhibi, Hassan</creator><general>Saudi Med J</general><general>Saudi Medical Journal</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0621-1234</orcidid></search><sort><creationdate>20210201</creationdate><title>Saudi Arabia Guidelines for diabetic macular edema A consensus of the Saudi Retina Group</title><author>AlQahtani, Abdullah S. ; Hazzazi, Mohammad A. ; Waheeb, Saad A. ; Semidey, Valmore A. ; Elgendy, Hussein K. ; Alkhars, Wafeeha ; Abouammoh, Marwan A. ; Al-Dhibi, Hassan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-c147c891692deca2dc18655633d409ec904aae33fc20aad5504634f8581fafa23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Care and treatment</topic><topic>Causes of</topic><topic>Clinical Practice Guidelines</topic><topic>Diabetic retinopathy</topic><topic>Diagnosis</topic><topic>Eye diseases</topic><topic>General & Internal Medicine</topic><topic>Life Sciences & Biomedicine</topic><topic>Medicine, General & Internal</topic><topic>Practice guidelines (Medicine)</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>AlQahtani, Abdullah S.</creatorcontrib><creatorcontrib>Hazzazi, Mohammad A.</creatorcontrib><creatorcontrib>Waheeb, Saad A.</creatorcontrib><creatorcontrib>Semidey, Valmore A.</creatorcontrib><creatorcontrib>Elgendy, Hussein K.</creatorcontrib><creatorcontrib>Alkhars, Wafeeha</creatorcontrib><creatorcontrib>Abouammoh, Marwan A.</creatorcontrib><creatorcontrib>Al-Dhibi, Hassan</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Saudi medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>AlQahtani, Abdullah S.</au><au>Hazzazi, Mohammad A.</au><au>Waheeb, Saad A.</au><au>Semidey, Valmore A.</au><au>Elgendy, Hussein K.</au><au>Alkhars, Wafeeha</au><au>Abouammoh, Marwan A.</au><au>Al-Dhibi, Hassan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Saudi Arabia Guidelines for diabetic macular edema A consensus of the Saudi Retina Group</atitle><jtitle>Saudi medical journal</jtitle><stitle>SAUDI MED J</stitle><addtitle>Saudi Med J</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>42</volume><issue>2</issue><spage>131</spage><epage>145</epage><pages>131-145</pages><issn>0379-5284</issn><eissn>1658-3175</eissn><abstract>Diabetes mellitus (DM) and its complications are major public health burdens in Saudi Arabia. The prevalence of diabetic retinopathy (DR) is 19.7% and the prevalence of diabetic macular edema (DME) is 5.7% in Saudi Arabia. Diabetic macular edema is a vision-threatening complication of DR and a major cause of vision loss worldwide. Ocular treatments include retinal laser photocoagulation, anti-vascular endothelial growth factor (anti-VEGF) agents, intravitreal corticosteroids, and vitreoretinal surgery when necessary. The present consensus was developed as a part of the Saudi Retina Group's efforts to generate Saudi guidelines and consensus for the management of DME, including recommendations for its diagnosis, treatment, and best practice. The experts' panel stipulates that the treatment algorithm should be categorized according to the presence of central macula involvement. In patients with no central macular involvement, laser photocoagulation is recommended as the first-line option. Patients with central macular involvement and no recent history of cardiovascular (CVS) or cerebrovascular disorders can be offered anti-VEGF agents as the first-line option. In the case of non-responders (defined as an improvement of <20% in optical coherence tomography or a gain of fewer than 5 letters in vision), switching to another anti-VEGF agent or steroids should be considered after 3 injections. Within the class of steroids, dexamethasone implants are recommended as the first choice. In patients with a recent history of CVS events, the use of anti-VEGF agents is not recommended, regardless of their lens status. The experts' panel recommends that a future study be conducted to provide a cut-off point for early switching to steroid implants in pseudo-phakic eyes.</abstract><cop>RIYADH</cop><pub>Saudi Med J</pub><pmid>33563731</pmid><doi>10.15537/smj.2021.2.25623</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-0621-1234</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0379-5284 |
| ispartof | Saudi medical journal, 2021-02, Vol.42 (2), p.131-145 |
| issn | 0379-5284 1658-3175 |
| language | eng |
| recordid | cdi_webofscience_primary_000619808700001 |
| source | PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Care and treatment Causes of Clinical Practice Guidelines Diabetic retinopathy Diagnosis Eye diseases General & Internal Medicine Life Sciences & Biomedicine Medicine, General & Internal Practice guidelines (Medicine) Science & Technology |
| title | Saudi Arabia Guidelines for diabetic macular edema A consensus of the Saudi Retina Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T04%3A26%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Saudi%20Arabia%20Guidelines%20for%20diabetic%20macular%20edema%20A%20consensus%20of%20the%20Saudi%20Retina%20Group&rft.jtitle=Saudi%20medical%20journal&rft.au=AlQahtani,%20Abdullah%20S.&rft.date=2021-02-01&rft.volume=42&rft.issue=2&rft.spage=131&rft.epage=145&rft.pages=131-145&rft.issn=0379-5284&rft.eissn=1658-3175&rft_id=info:doi/10.15537/smj.2021.2.25623&rft_dat=%3Cgale_webof%3EA652179152%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33563731&rft_galeid=A652179152&rfr_iscdi=true |